BPC-157 vs TB-500: Structure, Origin, and Research Focus Compared

Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.

BPC-157 and TB-500 are listed next to each other in almost every research-peptide catalog, and they are often sold together as a blend. This article compares the two at the level of chemistry, origin, proposed molecular target, and the quality of the published literature, and explains what a certificate for each (or for the Wolverine blend) has to show.

The short answer: two unrelated molecules that happen to share a shelf

BPC-157 is a 15-residue synthetic peptide whose sequence was taken from a protein fraction found in human gastric juice. TB-500 is a product name that vendors attach to synthetic thymosin beta-4, a 43-residue actin-binding protein, or to a short fragment of it. The two have no sequence relationship, differ in mass by more than threefold, and are studied in different model systems for different mechanistic reasons. The only thing they genuinely share is a soft-tissue research literature built mostly on rodent models, which is why they are paired commercially.

Neither compound is an approved drug anywhere in the world. Both were placed on an FDA list of compounding substances with safety concerns in 2023, were moved off that category in April 2026, and were reviewed by an FDA advisory committee in July 2026 without any final listing decision at the time of writing. Those events are covered in the regulatory section below, and in more depth in our FDA status table.

BPC-157: a pentadecapeptide from gastric juice

BPC-157 is the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a monoisotopic mass near 1,419 Da. It is a synthetic partial sequence of a larger protein that a Zagreb research group isolated from human gastric juice and named "body protection compound"; the 1993 overview by Sikiric and colleagues in Journal of Physiology (Paris) describes the isolation and the group's stomach-centered working hypothesis. The same paper reports that the peptide remains intact in human gastric juice for an extended period, which is the origin of the "stable gastric pentadecapeptide" phrase that still appears in paper titles.

Chemically, the sequence is proline-rich, carries three acidic residues (one Glu, two Asp) and one basic residue (Lys), and contains no cysteine, methionine, or tryptophan. That matters for a laboratory because it means there is no disulfide to scramble and no obvious oxidation hot spot; the main degradation risk in solution is slow hydrolysis rather than oxidation. Research-grade material is normally supplied as an acetate salt, and the counter-ion should be stated on the certificate (see TFA salt vs acetate salt).

No receptor for BPC-157 has been identified. The mechanistic literature is almost entirely in vitro and rodent. A 2011 Journal of Applied Physiology study from Chang and colleagues reported that BPC-157 increased outgrowth of rat Achilles tendon explants and the migration of cultured tendon fibroblasts, with changes in FAK and paxillin phosphorylation. A 2018 Current Pharmaceutical Design review by Seiwerth and colleagues frames the group's rodent findings alongside standard angiogenic growth factors. A 2025 literature-and-patent review in Pharmaceuticals by Józwiak and colleagues, written by a group outside Zagreb, notes that the compound has not been approved by the FDA or any other regulator and that peer-reviewed human data are essentially absent. One research group accounts for most of the rodent literature, which is itself a feature a reader should weigh. Our BPC-157 research overview walks through the literature by model system.

TB-500 and thymosin beta-4: a 43-residue actin-binding protein

Thymosin beta-4 (Tβ4) is a 43-residue, N-terminally acetylated, strongly acidic peptide with a molecular mass of about 4,963 Da. It is one of the most abundant small peptides in mammalian cells, and its defining biochemical job is to bind monomeric (G-) actin and hold it out of filament assembly. Safer, Elzinga and Nachmias showed in 1991 in the Journal of Biological Chemistry that Tβ4 and "Fx", a previously described actin-sequestering factor from platelets, are the same molecule. Huff and colleagues reviewed the whole beta-thymosin family in 2001, and Goldstein, Hannappel and Kleinman summarized the cell-biology literature in Trends in Molecular Medicine in 2005.

The actin-binding chemistry is unusually well mapped. Van Troys and colleagues used mutational analysis in a 1996 EMBO Journal paper to locate the central actin-binding motif at residues 17 to 22, the sequence Leu-Lys-Lys-Thr-Glu-Thr (LKKTET). Hertzog and colleagues then solved structures of beta-thymosin/WH2 domains bound to actin in a 2004 Cell paper, showing that the peptide is largely disordered in free solution and folds into an N-terminal helix plus the LKKTET segment on contact with actin, capping the monomer at both ends. This is a protein-protein interaction, not a receptor event, which separates Tβ4 mechanistically from almost everything else in a peptide catalog.

The name "TB-500" is where buyers need care. It is not an INN and has no fixed definition. Some listings use it for the full-length synthetic 43-mer; others use it for the short acetylated fragment Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (about 889 Da), which contains the actin-binding motif but little else. FDA's 2026 compounding-review materials describe TB-500 as a thymosin beta-4 fragment. The practical consequence is that the certificate, not the product name, tells you what is in the vial: the identity line should state the sequence and an observed mass that matches it. Full-length Tβ4 also carries a methionine at position 6, so an oxidized (+16 Da) shoulder on the HPLC trace is a known artifact to look for. Our TB-500 and thymosin beta-4 overview covers the naming problem in detail.

Side-by-side: chemistry, origin, and evidence

The table makes the asymmetry visible. Tβ4 has decades of structural biochemistry behind it from independent laboratories, including a 2012 review by Goldstein and colleagues that also summarizes the human early-phase programs run on the full-length molecule. BPC-157 has a large volume of rodent publications but far less independent mechanistic work and no defined target.

Why the two are blended, and what a Wolverine certificate has to list

The pairing is a commercial convention, not a literature-derived combination. We did not locate a peer-reviewed study that tests BPC-157 and thymosin beta-4 together in any model system; what exists are separate rodent soft-tissue literatures that vendors have placed side by side. A laboratory that buys a blend should therefore regard it as two independent reagents in one vial, each of which needs its own documentation.

Because the two molecules differ so much in mass and hydrophobicity, they separate cleanly on reverse-phase HPLC: BPC-157 elutes early and Tβ4 much later, so co-elution is not the main analytical problem for this particular blend. The real questions for a blend certificate are (1) two identity lines, each with its own observed mass; (2) two purity values, each reported against its own main peak; and (3) a net content figure for each component that confirms the labeled mass ratio. A single "purity 99%" line with no per-component breakdown does not tell you whether the vial contains the stated ratio. Our guide to reading a blend certificate goes line by line, and peptide blends vs single compounds explains what research questions a blend can and cannot answer.

For documentation purposes, the single-compound listings for BPC-157 10 mg and TB-500 10 mg each carry a lot-matched certificate with identity by mass spectrometry, HPLC purity, net peptide content, endotoxin, sterility and heavy metals, posted on the product page before purchase. The Wolverine 10 mg + 10 mg listing reports the same panel per component.

Regulatory status of both compounds

Neither BPC-157 nor TB-500 is an approved drug in the United States or elsewhere, and neither has an active marketing application that we could find. In September 2023 FDA placed both, along with several other peptides, in "Category 2" of its interim 503A bulk-substance policy, a category for nominated compounding ingredients where the agency has identified significant safety risks; its stated concern for both was immunogenicity plus limited or absent human exposure data. In April 2026 FDA revised that list and moved a group of peptides including BPC-157 and TB-500 out of Category 2, and on July 23, 2026 its Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500 and MOTS-c as candidates for the 503A bulks list. Trade press reported narrow advisory votes in favor of several of them; the committee's votes are recommendations only, FDA's own reviewers had recommended against listing, and no final rule had been published when this article was written.

Two points follow for a research buyer. First, a compounding-list decision concerns pharmacies and would not make either compound an approved drug. Second, FDA's warning letters to research-peptide sellers in 2024 through 2026 turn on how a product is marketed, not on the label alone: a "research use only" statement does not protect a vendor whose website describes outcomes in people. US Prime Peptides sells both compounds strictly for in vitro research, which is why this article discusses structure and evidence rather than effects. For the broader picture see are research peptides legal in the United States. Sports-science laboratories should also note that the WADA Prohibited List names thymosin beta-4 and its derivatives, including TB-500, under section S2, and lists BPC-157 under S0.

Frequently Asked Questions

Is TB-500 the same thing as thymosin beta-4?

Not necessarily. TB-500 is a vendor name, not an official one, and it is used for both the full-length 43-residue synthetic thymosin beta-4 (about 4,963 Da) and for a 7-residue acetylated fragment containing the LKKTET actin-binding motif (about 889 Da). The certificate's identity line, with sequence and observed mass, is the only reliable way to know which one a vial contains.

Does BPC-157 have a known receptor?

No. No receptor for BPC-157 has been identified. Published mechanistic work is at the pathway level in cell culture and rodent models, for example FAK and paxillin phosphorylation in tendon fibroblasts and VEGFR2 signaling in endothelial cells, and most of it comes from a single research group.

Why do vendors sell BPC-157 and TB-500 together?

Because both have rodent soft-tissue literatures, so they are grouped commercially. We found no peer-reviewed study that tests the two together, and the two molecules are unrelated in sequence, size and proposed target. A blend should be documented as two separate compounds with per-component identity, purity and content.

Is either BPC-157 or TB-500 approved by the FDA?

No. Neither is an approved drug in any country. FDA placed both in Category 2 of its 503A compounding list in 2023, removed them from that category in April 2026, and took them to an advisory committee in July 2026; those steps concern pharmacy compounding and do not constitute drug approval. Research-grade vials are supplied for in vitro use only.

Citations

1. Sikirić P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327. PMID 8298609
2. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID 21030672
3. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. PMID 29998800
4. Józwiak M, Bauer M, Kamysz W, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID 40005999
5. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID 1999398
6. Van Troys M, Dewitte D, Goethals M, et al. The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO J. 1996;15(2):201-210. PMID 8617195
7. Hertzog M, van Heijenoort C, Didry D, et al. The beta-thymosin/WH2 domain; structural basis for the switch from inhibition to promotion of actin assembly. Cell. 2004;117(5):611-623. PMID 15163409
8. Huff T, Müller CS, Otto AM, et al. beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. PMID 11311852
9. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. PMID 16099219
10. Goldstein AL, Hannappel E, Sosne G, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID 22074294
11. US FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026). fda.gov
12. US FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov

This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.

Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.